Cargando…

Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma

BACKGROUND: Melanoma development and progression are significantly influenced by ferroptosis and the immune microenvironment. However, there are no reliable biomarkers for melanoma prognosis prediction based on ferroptosis and immunological response. METHODS: Ferroptosis-related genes (FRGs) were re...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Mingsui, Li, Yaling, Wang, Fang, Han, Jiande, Gao, Yali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715341/
https://www.ncbi.nlm.nih.gov/pubmed/36467505
http://dx.doi.org/10.1155/2022/1840361
_version_ 1784842425723781120
author Tang, Mingsui
Li, Yaling
Wang, Fang
Han, Jiande
Gao, Yali
author_facet Tang, Mingsui
Li, Yaling
Wang, Fang
Han, Jiande
Gao, Yali
author_sort Tang, Mingsui
collection PubMed
description BACKGROUND: Melanoma development and progression are significantly influenced by ferroptosis and the immune microenvironment. However, there are no reliable biomarkers for melanoma prognosis prediction based on ferroptosis and immunological response. METHODS: Ferroptosis-related genes (FRGs) were retrieved from the FerrDb website. Immune-related genes (IRGs) were collected in the ImmPort dataset. The TCGA (The Cancer Genome Atlas) and GSE65904 datasets both contained prognostic FRGs and IRGs. The model was created using multivariate Cox regression, the least absolute shrinkage and selection operator (LASSO) Cox regression analysis, and the analysis and comparison between the expression patterns of ferroptosis and immune cell infiltration were done. Last but not least, research was conducted to assess the expression and involvement of the genes in the comprehensive index of ferroptosis and immune (CIFI). RESULTS: Two prognostic ferroptosis- and immune-related markers (PDGFRB and FOXM1) were utilized to develop a CIFI. In various datasets and patient subgroups, CIFI exhibits consistent predictive performance. The fact that CIFI is an independent prognostic factor for melanoma patients was revealed. Patients in the CIFI-high group further exhibited immune-suppressive characteristics and had elevated ferroptosis gene expression levels. The results of in vitro research point to the possibility that the PDGFRB and FOXM1 genes function as oncogenes in melanoma. CONCLUSION: In this study, a novel prognostic classifier for melanoma patients was developed and validated using ferroptosis and immune expression profiles.
format Online
Article
Text
id pubmed-9715341
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-97153412022-12-02 Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma Tang, Mingsui Li, Yaling Wang, Fang Han, Jiande Gao, Yali J Oncol Research Article BACKGROUND: Melanoma development and progression are significantly influenced by ferroptosis and the immune microenvironment. However, there are no reliable biomarkers for melanoma prognosis prediction based on ferroptosis and immunological response. METHODS: Ferroptosis-related genes (FRGs) were retrieved from the FerrDb website. Immune-related genes (IRGs) were collected in the ImmPort dataset. The TCGA (The Cancer Genome Atlas) and GSE65904 datasets both contained prognostic FRGs and IRGs. The model was created using multivariate Cox regression, the least absolute shrinkage and selection operator (LASSO) Cox regression analysis, and the analysis and comparison between the expression patterns of ferroptosis and immune cell infiltration were done. Last but not least, research was conducted to assess the expression and involvement of the genes in the comprehensive index of ferroptosis and immune (CIFI). RESULTS: Two prognostic ferroptosis- and immune-related markers (PDGFRB and FOXM1) were utilized to develop a CIFI. In various datasets and patient subgroups, CIFI exhibits consistent predictive performance. The fact that CIFI is an independent prognostic factor for melanoma patients was revealed. Patients in the CIFI-high group further exhibited immune-suppressive characteristics and had elevated ferroptosis gene expression levels. The results of in vitro research point to the possibility that the PDGFRB and FOXM1 genes function as oncogenes in melanoma. CONCLUSION: In this study, a novel prognostic classifier for melanoma patients was developed and validated using ferroptosis and immune expression profiles. Hindawi 2022-11-24 /pmc/articles/PMC9715341/ /pubmed/36467505 http://dx.doi.org/10.1155/2022/1840361 Text en Copyright © 2022 Mingsui Tang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tang, Mingsui
Li, Yaling
Wang, Fang
Han, Jiande
Gao, Yali
Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma
title Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma
title_full Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma
title_fullStr Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma
title_full_unstemmed Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma
title_short Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma
title_sort development and validation of a combined ferroptosis and immune prognostic model for melanoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715341/
https://www.ncbi.nlm.nih.gov/pubmed/36467505
http://dx.doi.org/10.1155/2022/1840361
work_keys_str_mv AT tangmingsui developmentandvalidationofacombinedferroptosisandimmuneprognosticmodelformelanoma
AT liyaling developmentandvalidationofacombinedferroptosisandimmuneprognosticmodelformelanoma
AT wangfang developmentandvalidationofacombinedferroptosisandimmuneprognosticmodelformelanoma
AT hanjiande developmentandvalidationofacombinedferroptosisandimmuneprognosticmodelformelanoma
AT gaoyali developmentandvalidationofacombinedferroptosisandimmuneprognosticmodelformelanoma